TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Inclusion Criteria:

   - Female 18 years of age or older at the time the written informed consent is obtained

   - Gynecologic Oncology Group (GOG) Performance Status of 0 or 1

   - Life expectancy >= 3 months (per investigator opinion)

   - Histologically or cytologically documented invasive epithelial ovarian cancer, primary
   peritoneal cancer, or fallopian tube cancer (Subjects with pseudomyxoma ,
   mesothelioma, unknown primary tumor, sarcoma, or neuroendocrine histology, with
   borderline ovarian cancer, ie, subjects with low malignant potential tumors, and with
   clear cell or mucinous histology are excluded)

   - Subjects must have undergone surgery for ovarian cancer, primary peritoneal cancer, or
   fallopian tube cancer including at least a unilateral oophorectomy

   - Radiologically evaluable disease per Response Evaluation Criteria in Solid Tumors
   (RECIST) 1.1 with modifications

   - Subjects must have had one prior platinum-based chemotherapeutic regimen for
   management of primary disease containing carboplatin, cisplatin, or another
   organoplatinum compound. This initial treatment may have included intraperitoneal
   therapy, high-dose therapy, consolidation therapy, bevacizumab or extended therapy
   administered after surgical or non-surgical assessment.

   - Adequate organ and hematological function

   - Generally well controlled blood pressure with systolic blood pressure <= 140 mmHg and
   diastolic blood pressure <= 90 mmHg prior to randomization. The use of
   anti-hypertensive medications to control hypertension is permitted

   - Radiographically documented disease progression either on or following the last dose
   of prior chemotherapy regimen for epithelial ovarian cancer, primary peritoneal
   cancer, or fallopian tube cancer

Exclusion Criteria:

   - Subjects who have received more than 3 previous regimens of anti-cancer therapy for
   epithelial ovarian, primary peritoneal or fallopian tube cancers

   - Subjects who have received paclitaxel as consolidation therapy, maintenance, or
   monotherapy are excluded

   - Subjects with primary platinum-refractory disease

   - Subjects with platinum-free interval (PFI) > 12 months from their last platinum based
   therapy

   - Radiotherapy <= 14 days prior to randomization. Subjects must have recovered from all
   radiotherapy-related toxicities

   - Previous abdominal or pelvic radiotherapy

   - History of arterial or venous thromboembolism within 12 months prior to randomization

   - History of clinically significant bleeding within 6 months prior to randomization

   - History of central nervous system metastasis

   - Has not yet completed a 21 day washout period prior to randomization for any previous
   anti cancer systemic therapies (30 days for prior bevacizumab)

   - Enrolled in or has not yet completed at least 30 days (prior to randomization) since
   ending other investigational device or drug, or currently receiving other
   investigational treatments

   - Unresolved toxicities from prior systemic therapy that are Common Terminology Criteria
   for Adverse Events (CTCAE) Version 3.0 >= Grade 2 in severity except alopecia

   - Known active or ongoing infection (except uncomplicated urinary tract infection [UTI])
   within 14 days prior to randomization

   - Currently or previously treated with AMG 386, or other molecules that inhibit the
   angiopoietins or Tie2 receptor

   - Treatment within 30 days prior to randomization with strong immune modulators
   including but not limited to systemic cyclosporine, tacrolimus, sirolimus,
   mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, and
   lenalidomide

   - Clinically significant cardiovascular disease within 12 months prior to randomization

   - Major surgery within 28 days prior to randomization or still recovering from prior
   surgery

   - Minor surgical procedures, except placement of tunneled central venous access device
   within 3 days prior to randomization. Diagnostic laparoscopy is regarded as a minor
   surgical procedure.